Staidson Beijing Biopharma (300204) — Net Asset Momentum
Staidson Beijing Biopharma (300204) recorded a net asset momentum of -12.0% as of December 2025, with net assets of CN¥806.72 Million CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See net assets of Staidson Beijing Biopharma for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Staidson Beijing Biopharma Net Asset Momentum (2007–2025)
This chart tracks Staidson Beijing Biopharma's year-over-year net asset growth across 19 annual reporting periods from 2007 to 2025. The most recent momentum reading is -12.0%, with net assets of CN¥806.72 Million CNY as of December 2025. For live market cap and overall valuation, see Staidson Beijing Biopharma market cap and net worth.
Annual Net Asset History for Staidson Beijing Biopharma (2007–2025)
The table below shows the complete annual net asset history for Staidson Beijing Biopharma from 2007 to 2025, covering 19 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check Staidson Beijing Biopharma tangible net worth ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | CN¥806.72 Million | CN¥1.27 Billion | CN¥459.48 Million | ▼ -12.0% |
| 2024 | CN¥916.76 Million | CN¥1.15 Billion | CN¥232.85 Million | ▼ -10.2% |
| 2023 | CN¥1.02 Billion | CN¥1.33 Billion | CN¥311.55 Million | ▼ -24.6% |
| 2022 | CN¥1.35 Billion | CN¥1.67 Billion | CN¥315.45 Million | ▼ -12.7% |
| 2021 | CN¥1.55 Billion | CN¥1.83 Billion | CN¥276.25 Million | ▼ -2.3% |
| 2020 | CN¥1.59 Billion | CN¥1.86 Billion | CN¥268.70 Million | ▼ -2.9% |
| 2019 | CN¥1.64 Billion | CN¥1.86 Billion | CN¥227.18 Million | ▼ -33.5% |
| 2018 | CN¥2.46 Billion | CN¥2.77 Billion | CN¥314.30 Million | ▲ +11.2% |
| 2017 | CN¥2.21 Billion | CN¥2.63 Billion | CN¥419.14 Million | ▲ +15.2% |
| 2016 | CN¥1.92 Billion | CN¥2.35 Billion | CN¥432.32 Million | ▲ +13.9% |
| 2015 | CN¥1.68 Billion | CN¥2.07 Billion | CN¥387.06 Million | ▲ +11.2% |
| 2014 | CN¥1.51 Billion | CN¥1.81 Billion | CN¥297.54 Million | ▲ +15.2% |
| 2013 | CN¥1.31 Billion | CN¥1.57 Billion | CN¥255.47 Million | ▲ +5.9% |
| 2012 | CN¥1.24 Billion | CN¥1.43 Billion | CN¥192.15 Million | ▲ +12.6% |
| 2011 | CN¥1.10 Billion | CN¥1.15 Billion | CN¥47.32 Million | ▲ +563.0% |
| 2010 | CN¥166.23 Million | CN¥264.88 Million | CN¥98.66 Million | ▲ +38.9% |
| 2009 | CN¥119.72 Million | CN¥148.75 Million | CN¥29.03 Million | ▲ +90.6% |
| 2008 | CN¥62.82 Million | CN¥92.07 Million | CN¥29.25 Million | ▲ +85.5% |
| 2007 | CN¥33.87 Million | CN¥82.22 Million | CN¥48.35 Million | — |